{
    "2020-03-19": [
        [
            {
                "time": "",
                "original_text": "【万联医药】雄关漫道真如铁，而今迈步从头越——迈瑞医疗（300760）深度报告（下）",
                "features": {
                    "keywords": [
                        "万联医药",
                        "迈瑞医疗",
                        "深度报告"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康基医疗IPO诊断报告：“两票制”冲击销售模式，研发费用率远逊同行",
                "features": {
                    "keywords": [
                        "康基医疗",
                        "IPO",
                        "两票制",
                        "销售模式",
                        "研发费用率"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}